留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

实体器官移植受者侵袭性真菌病的临床治疗管理

ArnouxRobenson Jean, 周佩军. 实体器官移植受者侵袭性真菌病的临床治疗管理[J]. 器官移植, 2024, 15(1): 151-159. doi: 10.3969/j.issn.1674-7445.2023089
引用本文: ArnouxRobenson Jean, 周佩军. 实体器官移植受者侵袭性真菌病的临床治疗管理[J]. 器官移植, 2024, 15(1): 151-159. doi: 10.3969/j.issn.1674-7445.2023089
Arnoux Robenson Jean, Zhou Peijun. Clinical treatment and management of invasive fungal disease in recipients of solid organ transplantation[J]. ORGAN TRANSPLANTATION, 2024, 15(1): 151-159. doi: 10.3969/j.issn.1674-7445.2023089
Citation: Arnoux Robenson Jean, Zhou Peijun. Clinical treatment and management of invasive fungal disease in recipients of solid organ transplantation[J]. ORGAN TRANSPLANTATION, 2024, 15(1): 151-159. doi: 10.3969/j.issn.1674-7445.2023089

实体器官移植受者侵袭性真菌病的临床治疗管理

doi: 10.3969/j.issn.1674-7445.2023089
基金项目: 上海市保健医疗科研课题(202240032)
详细信息
    作者简介:
    通讯作者:

    周佩军(ORCID 0009-0009-1202-7589),博士,主任医师,研究方向为泌尿外科、肾移植、移植免疫学及泌尿系肿瘤,Email:peijunzhou@yahoo.com

  • 中图分类号: R617, S945.1+3

Clinical treatment and management of invasive fungal disease in recipients of solid organ transplantation

More Information
  • 摘要: 随着实体器官移植(SOT)的广泛开展,SOT受者术后侵袭性真菌病(IFD)的发生率呈逐年上升趋势。近年来,对于SOT受者预防性抗真菌治疗意识不断增强,随之也出现了真菌耐药问题,导致原有标准化抗真菌治疗的效果不理想。而药物相互作用、药物的肝肾毒性等问题,也是临床医师需面对的挑战。本文综述了目前三唑类、棘白菌素类以及多烯类抗真菌药物与免疫抑制药之间的药物相互作用和肝肾毒性等特征,并总结了目前不同种类SOT受者术后IFD的预防策略以及感染不同病原体导致IFD的治疗策略,旨在为器官移植及相关学科的医师提供参考。

     

  • [1] ASLAM S, ROTSTEIN C, AST Infectious Disease Community of Practice. Candida infections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13623. DOI: 10.1111/ctr.13623.
    [2] HOSSEINI-MOGHADDAM SM, OUÉDRAOGO A, NAYLOR KL, et al. Incidence and outcomes of invasive fungal infection among solid organ transplant recipients: a population-based cohort study[J]. Transpl Infect Dis, 2020, 22(2): e13250. DOI: 10.1111/tid.13250.
    [3] 蒋进发, 魏思东, 张宇, 等. 肝脏移植术后侵袭性真菌感染的临床特点分析[J]. 中华医院感染学杂志, 2014(8): 1998-2000. DOI: 10.11816/cn.ni.2014-135058.

    JIANG JF, WEI SD, ZHANG Y, et al. The clinical characteristics of invasive fungal infections after liver transplantation[J]. Chin J Nosocomiol, 2014(8): 1998-2000. DOI: 10.11816/cn.ni.2014-135058.
    [4] 中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国实体器官移植手术部位感染管理专家共识(2022版)[J]. 中华临床感染病杂志, 2022, 15(3): 164-175. DOI: 10.3760/cma.j.issn.1674-2397.2022.03.002.

    Branch of Organ Transplant Physician of Chinese Medical Doctor Association, Branch of Organ Transplantation of Chinese Medical Association. Chinese experts consensus on the management of surgical site infection in solid organ transplantation (2022 edition)[J]. Chin J Clin Infect Dis, 2022, 15(3): 164-175. DOI: 10.3760/cma.j.issn.1674-2397.2022.03.002.
    [5] 邓斐文. 实体器官移植术后真菌感染的防治[J]. 器官移植, 2022, 13(4): 488-454. DOI: 10.3969/j.issn.1674-7445.2022.04.006.

    DENG FW. Prevention and treatment of fungal infection after solid organ transplantation[J]. Organ Transplant, 2022, 13(4): 488-454. DOI: 10.3969/j.issn.1674-7445.2022.04.006.
    [6] 彭英楠, 边志磊, 曹伟杰, 等. 泊沙康唑与伏立康唑预防异基因造血干细胞移植后侵袭性真菌感染的疗效和安全性[J]. 实用医学杂志, 2023, 39(6): 742-746. DOI: 10.3969/j.issn.1006-5725.2023.06.015.

    PENG YN, BIAN ZL, CAO WJ, et al. Efficacy and safety study of posaconazole and voriconazole for the prevention of invasive fungal infections after allogeneic hematopoietic stem cell transplantation[J]. J Pract Med, 2023, 39(6): 742-746. DOI: 10.3969/j.issn.1006-5725.2023.06.015.
    [7] 孙浩, 杨振宇, 肇丽梅. 环孢素血药浓度异常患者的处置及分析[J]. 医药导报, 2021, 40(8): 1120-1123. DOI: 10.3870/j.issn.1004-0781.2021.08.025.

    SUN H, YANG ZY, ZHAO LM. Treatment and analysis of a case of abnormal blood concentration of cyclosporine[J]. Herald Med, 2021, 40(8): 1120-1123. DOI: 10.3870/j.issn.1004-0781.2021.08.025.
    [8] 王超, 呼自顺, 张弋, 等. 伏立康唑对肾移植受者他克莫司药代动力学影响的研究[J]. 中华器官移植杂志, 2019, 40(10): 615-619. DOI: 10.3760/cma.j.issn.0254-1785.2019.10.008.

    WANG C, HU ZS, ZHANG Y, et al. Effects of voriconazole on pharmacokinetics of tacrolimus in renal transplantation recipients[J]. Chin J Organ Transplant, 2019, 40(10): 615-619. DOI: 10.3760/cma.j.issn.0254-1785.2019.10.008.
    [9] 中华医学会器官移植学分会. 器官移植受者侵袭性真菌病临床诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(3): 227-236. DOI: 10.3969/j.issn.1674-7445.2019.03.002.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specification for clinical diagnosis and treatment of invasive fungal disease in organ transplant recipients (2019 edition)[J]. Organ transplant, 2019, 10(3): 227-236. DOI: 10.3969/j.issn.1674-7445.2019.03.002.
    [10] 苏丹, 陈露, 张蕾, 等. 环孢素与唑类抗真菌药物相互作用的研究进展[J]. 广西医学, 2020, 42(5): 622-624. DOI: 10.11675/j.issn.0253-4304.2020.05.24.

    SU D, CHEN L, ZHANG L, et al. Research progress in the interactions between cyclosporine and azole antifungal drugs[J]. Guangxi Med J, 2020, 42(5): 622-624. DOI: 10.11675/j.issn.0253-4304.2020.05.24.
    [11] EMOTO C, VINKS AA, FUKUDA T. Risk assessment of drug-drug interactions of calcineurin inhibitors affecting sirolimus pharmacokinetics in renal transplant patients[J]. Ther Drug Monit, 2016, 38(5): 607-613. DOI: 10.1097/FTD.0000000000000314.
    [12] VANHOVE T, BOUWSMA H, HILBRANDS L, et al. Determinants of the magnitude of interaction between tacrolimus and voriconazole/posaconazole in solid organ recipients[J]. Am J Transplant, 2017, 17(9): 2372-2380. DOI: 10.1111/ajt.14232.
    [13] ZHU LE, HUANG HP, CAI YP, et al. Effect of posaconazole on the concentration of intravenous and oral cyclosporine in patients undergoing hematopoietic stem cell transplantation[J]. Eur J Clin Pharmacol, 2022, 78(10): 1677-1685. DOI: 10.1007/s00228-022-03378-z.
    [14] 中国研究型医院学会肝病专业委员会重症肝病学组,中华医学会肝病学分会重型肝病与人工肝学组. 重症肝病合并侵袭性真菌感染诊治专家共识[J]. 中华肝脏病杂志, 2022, 30(2): 159-168. DOI: 10.3760/cma.j.cn501113-20220130-00053.

    Severe Liver Disease Group of the Liver Disease Professional Committee of the Chinese Research Hospital Association, Severe Liver Disease and Artificial Liver Group of Hepatology Branch of Chinese Medical Association. Consensus on diagnosis and treatment of invasive fungal infection in patients with severe liver disease[J]. Chin J Hepatol, 2022, 30(2): 159-168. DOI: 10.3760/cma.j.cn501113-20220130-00053.
    [15] ROBINSON DH, HUGHES CFM, GRIGG A. Optimal oral cyclosporin dosing with concomitant posaconazole post allogeneic stem cell transplantation[J]. Leuk Lymphoma, 2020, 61(10): 2448-2452. DOI: 10.1080/10428194.2020.1768381.
    [16] BOSE P, MCCUE D, WURSTER S, et al. Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study[J]. Clin Infect Dis, 2021, 72(10): 1755-1763. DOI: 10.1093/cid/ciaa358.
    [17] 陈欣, 林韧. 艾沙康唑临床应用专家共识(2023版)[J]. 临床血液学杂志, 2023, 36(5): 295-302. DOI: 10.13201/j.issn.1004-2806.2023.05.001.

    CHEN X, LIN R. Expert consensus on the clinical use of isavuconazole(2023 edition)[J]. J Clin Hematol, 2023, 36(5): 295-302. DOI: 10.13201/j.issn.1004-2806.2023.05.001.
    [18] SZYMAŃSKI M, CHMIELEWSKA S, CZYŻEWSKA U, et al. Echinocandins - structure, mechanism of action and use in antifungal therapy[J]. J Enzyme Inhib Med Chem, 2022, 37(1): 876-894. DOI: 10.1080/14756366.2022.2050224.
    [19] CHEN SC, SLAVIN MA, SORRELL TC. Echinocandin antifungal drugs in fungal infections: a comparison[J]. Drugs, 2011, 71(1): 11-41. DOI: 10.2165/11585270-000000000-00000.
    [20] MENNA P, SALVATORELLI E, DEL PRINCIPE MI, et al. Choosing antifungals for the midostaurin-treated patient: does CYP3A4 outweigh recommendations? a brief insight from real life[J]. Chemotherapy, 2021, 66(1/2): 47-52. DOI: 10.1159/000513989.
    [21] CAVASSIN FB, BAÚ-CARNEIRO JL, VILAS-BOAS RR, et al. Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections[J]. Infect Dis Ther, 2021, 10(1): 115-147. DOI: 10.1007/s40121-020-00382-7.
    [22] GÓMEZ-LÓPEZ A. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation[J]. Clin Microbiol Infect, 2020, 26(11): 1481-1487. DOI: 10.1016/j.cmi.2020.05.037.
    [23] NIVOIX Y, LEDOUX MP, HERBRECHT R. Antifungal therapy: new and evolving therapies[J]. Semin Respir Crit Care Med, 2020, 41(1): 158-174. DOI: 10.1055/s-0039-3400291.
    [24] 孔旭东, 王晓星, 陈玥, 等. 两性霉素B不同制剂的药学特性和临床应用[J]. 临床药物治疗杂志, 2022, 20(7): 7-12. DOI: 10.3969/j.issn.1672-3384.2022.07.002.

    KONG XD, WANG XX, CHEN Y, et al. Pharmaceutical properties and clinical applications of different formulations of amphotericin B[J]. Clin Med J, 2022, 20(7): 7-12. DOI: 10.3969/j.issn.1672-3384.2022.07.002.
    [25] 梁官钊, 刘维达. 2019年欧洲毛霉病诊疗指南解读[J]. 中国真菌学杂志, 2021, 16(2): 116-120.

    LIANG GZ, LIU WD. Interpretation of european mucormycosis diagnosis and treatment guidelines in 2019[J]. Chin J Mycol, 2021, 16(2): 116-120.
    [26] Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living with HIV [M]. Geneva: World Health Organization, 2022.
    [27] KOEHLER P, BASSETTI M, CHAKRABARTI A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance[J]. Lancet Infect Dis, 2021, 21(6): e149-e162. DOI: 10.1016/S1473-3099(20)30847-1.
    [28] 王吉耀, 葛均波, 邹和建. 实用内科学(上册)[M]. 北京: 人民卫生出版社, 2022.
    [29] 中华医学会器官移植学分会肺移植学组. 中国肺移植受者侵袭性真菌病临床诊疗规范[J]. 中华器官移植杂志, 2021, 42(12): 705-711. DOI: 10.3760/cma.j.issn 421203-20210914-00230.

    Lung Transplantation Group of Branch of Organ Transplantation of Chinese Medical Association. Clinical diagnosis and treatment of invasivefungal mycosis in Chinese lung transplant recipients[J]. Chin J Organ Transplant, 2021, 42(12): 705-711. DOI: 10.3760/cma.j.issn421203-20210914-00230.
    [30] RUIZ-CAMPS I, AGUADO JM, ALMIRANTE B, et al. Guidelines for the prevention of invasive mould diseases caused by filamentous fungi by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)[J]. Clin Microbiol Infect, 2011, 17(Suppl 2): 1-24. DOI: 10.1111/j.1469-0691.2011.03477.x.
    [31] HUSAIN S, CAMARGO JF. Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13544. DOI: 10.1111/ctr.13544.
    [32] PATTERSON TF, THOMPSON GR 3RD, DENNING DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 63(4): e1-e60. DOI: 10.1093/cid/ciw326.
    [33] KRIEGL L, BOYER J, EGGER M, et al. Antifungal stewardship in solid organ transplantation[J]. Transpl Infect Dis, 2022, 24(5): e13855. DOI: 10.1111/tid.13855.
    [34] GAVALDÀ J, MEIJE Y, FORTÚN J, et al. Invasive fungal infections in solid organ transplant recipients[J]. Clin Microbiol Infect, 2014, 20(Suppl 7): 27-48. DOI: 10.1111/1469-0691.12660.
    [35] KENNEDY CC, PENNINGTON KM, BEAM E, et al. Fungal infection in lung transplantation[J]. Semin Respir Crit Care Med, 2021, 42(3): 471-482. DOI: 10.1055/s-0041-1729173.
    [36] BARROS N, ROSENBLATT RE, PHIPPS MM, et al. Invasive fungal infections in liver diseases[J]. Hepatol Commun, 2023, 7(9): e0216. DOI: 10.1097/HC9.0000000000000216.
    [37] PAPPAS PG, KAUFFMAN CA, ANDES DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 62(4): e1-50. DOI: 10.1093/cid/civ933.
    [38] SEOK H, HUH K, CHO SY, et al. Invasive fungal diseases in kidney transplant recipients: risk factors for mortality[J]. J Clin Med, 2020, 9(6): 1824. DOI: 10.3390/jcm9061824.
    [39] ESCAMILLA JE, JANUARY SE, VAZQUEZ GUILLAMET R. Diagnosis and treatment of fungal infections in lung transplant recipients[J]. Pathogens, 2023, 12(5): 694. DOI: 10.3390/pathogens12050694.
    [40] PHOOMPOUNG P, VILLALOBOS APC, JAIN S, et al. Risk factors of invasive fungal infections in lung transplant recipients: a systematic review and meta-analysis[J]. J Heart Lung Transplant, 2022, 41(2): 255-262. DOI: 10.1016/j.healun.2021.09.014.
    [41] WARRIS A, LEHRNBECHER T, ROILIDES E, et al. ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children[J]. Clin Microbiol Infect, 2019, 25(9): 1096-1113. DOI: 10.1016/j.cmi.2019.05.019.
    [42] DOUGLAS AP, SMIBERT OC, BAJEL A, et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021[J]. Intern Med J, 2021, 51(Suppl 7): 143-176. DOI: 10.1111/imj.15591.
    [43] VERWEIJ PE, ANANDA-RAJAH M, ANDES D, et al. International expert opinion on the management of infection caused by azole-resistant aspergillus fumigatus[J]. Drug Resist Updat, 2015, 21/22: 30-40. DOI: 10.1016/j.drup.2015.08.001.
    [44] 王会伟, 蔡良奇, 李航, 等. 1982至2020年中国肾移植受者合并隐球菌病的系统分析[J]. 菌物学报, 2021, 40(4): 707-720. DOI: 10.13346/j.mycosystema.200372.

    WANG HW, CAI LQ, LI H, et al. Systematic analysis of secondary and complicated cryptococcosis in renal transplant recipients in China(1982-2020)[J]. Mycosystema, 2021, 40(4): 707-720. DOI: 10.13346/j.mycosystema.200372.
    [45] TARDIEU L, DIVARD G, LORTHOLARY O, et al. Cryptococcal meningitis in kidney transplant recipients: a two-decade cohort study in France[J]. Pathogens, 2022, 11(6): 699. DOI: 10.3390/pathogens11060699.
    [46] 中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 中国艾滋病性病, 2021, 27(11): 1182-1201. DOI: 10.13419/j.cnki.aids.2021.11.02.

    HIV/AIDS Hepatitis C Group of Infectious Diseases Branch of Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS ( 2021 edition)[J]. Chin J AIDS STD, 2021, 27(11): 1182-1201. DOI: 10.13419/j.cnki.aids.2021.11.02.
    [47] RYOM L, COTTER A, DE MIGUEL R, et al. 2019 update of the European AIDS Clinical Society guidelines for treatment of people living with HIV version 10.0[J]. HIV Med, 2020, 21(10): 617-624. DOI: 10.1111/hiv.12878.
    [48] GRAS J, TAMZALI Y, DENIS B, et al. Cryptococcus neoformans meningitis in kidney transplant recipients: a diagnostic and therapeutic challenge[J]. Med Mycol Case Rep, 2021, 32: 84-87. DOI: 10.1016/j.mmcr.2021.04.005.
    [49] BADDLEY JW, FORREST GN, AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplantation-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13543. DOI: 10.1111/ctr.13543.
    [50] TOGANO T, SUZUKI Y, NAKAMURA F, et al. Epidemiology of visceral mycoses in patients with acute leukemia and myelodysplastic syndrome: analyzing the national autopsy database in Japan[J]. Med Mycol, 2021, 59(1): 50-57. DOI: 10.1093/mmy/myaa029.
    [51] SHARMA M, RUDRAMURTHY SM, CHAKRABARTI A. Epidemiology of invasive fungal infections in solid organ transplant recipients: an indian perspective[J]. Curr Fungal Infect Rep, 2022, 16(4): 179-187. DOI: 10.1007/s12281-022-00446-w.
    [52] MUTHU V, AGARWAL R, DHOORIA S, et al. Has the mortality from pulmonary mucormycosis changed over time? a systematic review and meta-analysis[J]. Clin Microbiol Infect, 2021, 27(4): 538-549. DOI: 10.1016/j.cmi.2020.12.035.
    [53] 何绍平, 叶远馨, 王曼晋, 等. 肾移植并发肺孢子菌肺炎82例临床特征分析[J]. 华西医学, 2021, 36(3): 374-378. DOI: 10.7507/1002-0179.202010076.

    HE SP, YE YX, WANG MJ, et al. Clinical features of 82 renal transplant recipients complicated with pneumocystis carinii pneumonia[J]. West China Med J, 2021, 36(3): 374-378. DOI: 10.7507/1002-0179.202010076.
    [54] 张春燕, 弓震琼. 肾移植术后致耶氏肺孢子菌肺炎患者抗感染治疗的分析与监护[J]. 药学实践杂志, 2022, 40(5): 477-480. DOI: 10.12206/j.issn.2097-2024.202108037.

    ZHANG CY, GONG ZQ. Pharmaceutical care in a case of patient with pneumocystis jiroveci pneumonia after renal transplantation[J]. J Pharm Serv, 2022, 40(5): 477-480. DOI: 10.12206/j.issn.2097-2024.202108037.
    [55] MASCHMEYER G, HELWEG-LARSEN J, PAGANO L, et al. ECIL guidelines for treatment of pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients[J]. J Antimicrob Chemother, 2016, 71(9): 2405-2413. DOI: 10.1093/jac/dkw158.
    [56] DE BOER MG, DE FIJTER JW, KROON FP. Outbreaks and clustering of pneumocystis pneumonia in kidney transplant recipients: a systematic review[J]. Med Mycol, 2011, 49(7): 673-680. DOI: 10.3109/13693786.2011.571294.
    [57] RADISIC M, LATTES R, CHAPMAN JF, et al. Risk factors for pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study[J]. Transpl Infect Dis, 2003, 5(2): 84-93. DOI: 10.1034/j.1399-3062.2003.00018.x.
    [58] PAN J, FU Y, CAO Y, et al. Single-center retrospective analysis of prophylaxis and treatment of pneumocystis carinii pneumonia in patients with renal dysfunction after renal transplantation[J]. Ann Transplant, 2020, 25: e925126. DOI: 10.12659/AOT.925126.
    [59] 刘永光, 郭颖, 李民, 等. 肾移植后并发卡氏肺孢子虫肺炎36例资料回顾[J]. 中国组织工程研究与临床康复, 2010, 14(53): 10063-10066. DOI: 10.3969/j.issn.1673-8225.2010.53.044.

    LIU YG, GUO Y, LI M, et al. Pneumocystis carinii pneumonia following renal transplantation a retrospective study of 36 cases[J]. Chin J Tissue Eng Res, 2010, 14(53): 10063-10066. DOI: 10.3969/j.issn.1673-8225.2010.53.044.
    [60] 沈泽, 田洋洋, 周政, 等. 肾移植受者耶氏肺孢子菌肺炎的临床及流行病学特征分析[J]. 器官移植, 2023, 14(4): 570-577. DOI: 10.3969/j.issn.1674-7445.2023.04.014.

    SHEN Z, TIAN YY, ZHOU Z, et al. Clinical and epidemiological features analysis of pneumocystis jirovecii pneumonia in kidney transplant recipients[J]. Organ Transplant, 2023, 14(4): 570-577. DOI: 10.3969/j.issn.1674-7445.2023.04.014.
    [61] NOVAK AR, BRADLEY ME, KISER TH, et al. Azole-resistant aspergillus and echinocandin-resistant candida - what are the treatment options?[J]. Curr Fungal Infect Rep, 2020, 14(2): 141-152. DOI: 10.1007/s12281-020-00379-2.
    [62] 孔旭东, 李少强, 陈玥,等. 两性霉素B脂质体的药学特点和临床应用[J]. 临床药物治疗杂志, 2023, 21(11): 6-11.

    KONG XD, LI SQ, CHEN Y, et al. Pharmaceutical characteristics and clinical applications of liposomal amphotericin B[J]. Clin Med J, 2023, 21(11): 6-11.
  • 加载中
图(1)
计量
  • 文章访问数:  184
  • HTML全文浏览量:  55
  • PDF下载量:  30
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-10-07
  • 录用日期:  2023-11-27
  • 刊出日期:  2024-01-11

目录

    /

    返回文章
    返回